Investment Rating - The report maintains a "Positive" investment rating for the non-ferrous metals industry in China [5] Core Views - The report emphasizes a long-term perspective in the non-ferrous metals sector, particularly in light of recent volatility in precious metals prices, suggesting that while short-term fluctuations may occur, the long-term bullish trend remains intact [7][12] - The zinc sector is highlighted as an overlooked opportunity, driven by the demand from re-industrialization in Asia, Africa, and Latin America, which is expected to support prices [13] - The copper sector is viewed positively due to the historical high gold-to-copper ratio, indicating potential for price increases in copper as industrial demand grows [14] - The precious metals sector is advised to wait for price stabilization before making significant investments, despite a long-term bullish outlook [15] Summary by Sections 1. Core Views - The report stresses the importance of a long-term investment strategy in the non-ferrous metals market, particularly in precious metals, which have experienced significant price fluctuations recently [12] - Zinc is identified as a critical material benefiting from global re-industrialization trends, with supply tightness expected to support price increases [13] - Copper is projected to continue its upward trajectory due to favorable market conditions and supply constraints [14] - Investors in precious metals are advised to be cautious in the short term while maintaining a long-term bullish outlook [15] 2. Steel Industry - The steel industry is currently facing a weak fundamental backdrop as it approaches the seasonal low around the Spring Festival, with slight declines in iron and steel production [16] - Inventory levels show a divergence between social and steel mill stocks, indicating potential market adjustments [23] - Overall steel prices have seen a minor decline, reflecting broader market trends [35] 3. New Energy Metals - Lithium carbonate production saw a significant year-on-year increase of 69.09% in December 2025, indicating strong supply growth in the new energy sector [39] - The demand for new energy vehicles remains robust, with production and sales showing notable year-on-year growth [43] - Prices for lithium and nickel have shown recent declines, while cobalt prices have remained stable [48]

Investment Rating - The report maintains a "Positive" investment rating for the non-ferrous metals industry in China [5] Core Views - The report emphasizes a long-term perspective on the market, suggesting that despite short-term volatility in precious metals, the long-term bull market remains intact due to unresolved U.S. debt issues [7][12] - The zinc sector is highlighted as an overlooked material benefiting from the re-industrialization in Asia, Africa, and Latin America, with expectations for price increases due to supply tightness [7][13] - The copper sector is viewed positively, with the gold-to-copper ratio reaching historical highs, indicating potential for copper price increases amid supply constraints [7][14] - For precious metals, investors are advised to wait for price stabilization before increasing positions, as significant price fluctuations have been observed recently [7][15] Summary by Sections 1. Non-Ferrous Metals - The report discusses the dynamics of precious metals, noting significant price drops in gold and silver, with gold prices reaching $4,880 per ounce and silver prices at $85 per ounce during a recent week [7][12] - The zinc market is expected to benefit from increased demand driven by infrastructure projects in developing regions, with a noted decrease in zinc smelting fees indicating supply constraints [7][13] - The copper market is projected to maintain upward momentum due to a high gold-to-copper ratio and ongoing supply challenges from major mining companies [7][14] - The report suggests a cautious approach to precious metals, recommending that investors wait for market stabilization before making new investments [7][15] 2. Steel Industry - The steel industry is experiencing a weak fundamental outlook as it approaches the seasonal low around the Spring Festival, with a slight decrease in iron output and weakening demand for rebar [16][21] - Inventory levels show a divergence between social and steel mill stocks, with total steel inventory at 891 thousand tons, reflecting a 2.56% weekly increase [23] - Steel prices have generally declined, with the overall steel price index down by 0.20%, and specific products like cold-rolled steel experiencing a 0.44% decrease [35][36] 3. New Energy Metals - Lithium carbonate production in December 2025 saw a significant year-on-year increase of 69.09%, indicating strong supply growth in the new energy sector [39] - The demand for new energy vehicles remains robust, with December 2025 production reaching 1.5858 million units, a 9.02% increase year-on-year [43] - Lithium prices have shown a notable decline, with the average price for battery-grade lithium carbonate at 159,500 yuan per ton, reflecting a 5.62% decrease [48][49]

Group 1 - The report indicates that the recent market adjustment pressure has been released, leading to a rebound, with popular sectors experiencing valuation recovery [6] - It maintains a cautiously optimistic view for February, suggesting that while the A-share index may struggle, there is potential for valuation recovery in the H-share market [6] - The report emphasizes the importance of mid-cap blue-chip stocks, particularly in the agricultural sector, as they are expected to continue performing well due to their risk characteristics [6] Group 2 - The renewable energy sector is highlighted as a cornerstone for carbon reduction, with significant growth expected in wind and solar installations during the 14th Five-Year Plan period [3] - The report anticipates over 50% growth in energy storage installations by 2025, driven by high demand in the renewable energy sector [3] - It suggests focusing on high-growth technology-related stocks within the renewable energy space [3] Group 3 - The report discusses the increasing certainty of mass production for humanoid robots, particularly with Tesla's advancements in this area [4] - It identifies investment opportunities in components related to robotics, such as sensors and flexible protective layers, as the industry moves towards more human-like robots [4] - Companies with proven manufacturing and management capabilities in automotive and machinery parts are expected to gain higher market shares [4]

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 53.84 CNY [4][7]. Core Insights - The company's short-term performance is under pressure due to intensified competition and policy impacts, leading to a downward revision of revenue and profit forecasts for 2025-2026 [4][10]. - Despite the short-term challenges, the company has significant long-term growth potential driven by self-research and innovation transformation [4][10]. - The company is expected to leverage its integrated service capabilities in contract research and development (CRO) and contract development and manufacturing organization (CDMO) to enhance its business structure and return to a growth trajectory [10]. - The company has a robust pipeline of self-researched products, with 132 projects under development, including 37 approved projects, which are anticipated to contribute positively to future revenues [10]. - The company is actively transitioning to innovative drug development, with 15 ongoing projects in critical therapeutic areas, which could provide a second growth curve through partnerships and milestone payments [10]. Financial Summary - Revenue is projected to decline from 1,017 million CNY in 2023 to 696 million CNY in 2025, with a recovery expected in subsequent years [6][12]. - The net profit attributable to the parent company is forecasted to be a loss of 53 million CNY in 2024, with a gradual return to profitability by 2026 [6][12]. - The earnings per share (EPS) is expected to drop to -0.63 CNY in 2025, before recovering to 0.37 CNY in 2026 and 0.61 CNY in 2027 [6][12]. - The gross margin is projected to decrease from 65.5% in 2023 to 52.0% in 2024, with a gradual recovery thereafter [6][12].

Group 1 - The report maintains a positive outlook on mid-cap blue chips, with a focus on price increases in the chemical and agricultural sectors [6][27] - Liquidity expectations are shifting, leading to increased volatility in non-ferrous metals, while the demand for industrial products driven by AI capital expenditure is expected to support price increases in cyclical goods [6][27] - Agricultural products are anticipated to experience a comprehensive price increase due to upstream price transmission and a tight supply-demand balance in major commodities like sugar, corn, and oilseeds [12][27] Group 2 - The trading sentiment across large, mid, and small-cap stocks has cooled, but medium-term uncertainty remains relatively stable [17][27] - The trend for mid-cap blue chips related to cyclical sectors (non-ferrous metals and basic chemicals) remains strong, while media and defense industries are showing strengthening trends [20][27] - Short-term uncertainty is rising for non-ferrous metals and petrochemicals, while medium-term uncertainty for basic chemicals is stable and for agriculture is declining [23][27]

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 53.84 CNY [4][7]. Core Insights - The company's short-term performance is under pressure due to intensified competition and policy impacts, leading to a downward revision of revenue and profit forecasts for 2025-2026 [4][10]. - Despite the short-term challenges, the company has significant long-term growth potential driven by self-research and innovation transformation [4][10]. - The company is expected to leverage its integrated service capabilities in contract research and development (CRO) and contract development and manufacturing organization (CDMO) to enhance its business structure and return to a growth trajectory [10]. - The company has a robust pipeline of self-researched products, with 132 projects under development, including 37 approved products, which are anticipated to contribute to stable revenue growth as they enter commercialization [10]. - The company is actively transitioning to innovative drug development, with 15 ongoing projects in key therapeutic areas, which could provide a second growth curve through partnerships and milestone payments [10]. Financial Summary - Revenue is projected to decline from 1,017 million CNY in 2023 to 696 million CNY in 2025, with a recovery to 889 million CNY by 2027 [6]. - The net profit attributable to the parent company is expected to turn negative in 2024 and 2025, with forecasts of -53 million CNY and -69 million CNY respectively, before recovering to 67 million CNY in 2027 [6]. - The earnings per share (EPS) is forecasted to be -0.63 CNY in 2025, with a recovery to 0.61 CNY by 2027 [6]. - The gross margin is expected to decrease from 65.5% in 2023 to 52.0% in 2024, before gradually improving to 56.4% by 2027 [6].

1. Report Industry Investment Rating - The report does not mention the industry investment rating [1][2] 2. Core Views of the Report - The current agricultural sector has investment value due to upstream price transmission, and agricultural products are expected to rise comprehensively. The current allocation of the agricultural sector by funds is low, and there is potential for growth when incremental funds enter the market [5][8] - There are both comprehensive and theme - focused agricultural - related indices, with distinct small - and medium - cap characteristics, reasonable valuations, and different performance in terms of stability and elasticity [5] - Recommended representative ETFs include those related to overall agriculture, livestock breeding, and grain and seed industries [5] 3. Summary by Directory 3.1 Current Agricultural Sector Investment Value Analysis 3.1.1 Upstream Price Transmission, Agricultural Products Expected to Rise Comprehensively - Some agricultural products are at the starting point of price increase, and the balance of supply and demand is fragile. Upstream resource price increases and geopolitical disturbances can disrupt the supply - demand balance and push up prices. Rising production factor costs will clear out inefficient enterprises [8] - Two investment paths are recommended: paying attention to products whose supply - demand balance is disrupted by external factors, and industries that are expected to start a new round of growth after price increases, such as the pig - breeding industry [8][9] 3.1.2 Currently, Funds are Under - Allocated to the Agricultural Sector - Active equity funds' allocation to the agricultural sector is less than 0.5%. The proportion of the agricultural sector in the A - share market is 1.31%, indicating an under - allocation. The scale of agricultural - related ETFs accounts for only 0.87% of the total A - share industry ETFs, while the chemical industry has experienced growth in both price and scale. The agricultural sector has growth potential when incremental funds enter [10] 3.2 Current Agricultural - Related Index Investment Value Analysis 3.2.1 Compilation Scheme Features: Meeting Various Investment Sharpness - The 8 agricultural - related indices can be divided into two categories: comprehensive industry indices (covering the entire industrial chain) and theme - focused indices. The former is suitable for investors optimistic about the overall development of agriculture, and the latter is for those with specific investment needs [18][19] 3.2.2 Positioning Style: Distinct Small - and Medium - Cap Characteristics, with Different Emphases and Features - In terms of market value, most indices have small - and medium - cap characteristics, with the "Big Agriculture" index having relatively large - cap components, and the "Agriculture, Animal Husbandry and Fishery" and "Livestock Breeding" indices having relatively small - cap components [25] - In terms of position characteristics, different indices have different emphases in sub - industries. Comprehensive industry indices cover the entire industrial chain, while theme - focused indices have more specific focuses [27][28][30] 3.2.3 Valuation Level: Overall Valuation is Reasonable, with Relatively Strong Attractiveness - The current price - to - earnings ratios (TTM) of the 8 agricultural - related indices are between 15 - 30 times, mostly at the bottom 50% of the past ten - year percentile. The price - to - book ratios are mostly between 2.5 - 3, also at the bottom 50% of the past ten - year percentile, indicating reasonable valuations [36] 3.2.4 Performance: Performance Elasticity and Stability - In the long - term, comprehensive agricultural indices have relatively strong performance stability, while theme - focused indices have greater performance elasticity. The annualized return of the "Guozheng Grain" index in the past ten years is 11%, and the returns of other indices are mostly within 5% [42] 3.3 Representative ETF Product References - If optimistic about the overall development of agriculture, consider the Fuguo Agriculture ETF (159825) [47] - If focusing on investment opportunities in the livestock - breeding sector, consider the Cathay Pacific Breeding ETF (159865), Penghua Livestock ETF (159867), Ping An Breeding ETF (516760), and Yongying Breeding ETF (159165) [47] - If focusing on investment opportunities in the grain and seed industries, consider the Penghua Grain ETF (159698) [48]

Investment Rating - The industry investment rating is "Positive" (maintained) [6] Core Insights - The report highlights the significant commercial value of extrahepatic delivery technology for small nucleic acid drugs, which is expanding from liver diseases to multiple disease areas. Domestic companies are rapidly developing multi-target drugs and extrahepatic delivery platforms, which are expected to accelerate the release of potential clinical value [3][8] - The report emphasizes that multinational corporations (MNCs) are intensifying their focus on next-generation delivery platforms, moving from "liver validation" to "multi-organ expansion." This shift is crucial as it addresses unmet clinical needs in various tissues such as fat, muscle, central nervous system, heart, and kidneys [8] - The report indicates that 2026 is a pivotal year for small nucleic acid therapies, with domestic innovative drugs expected to become core assets for transactions. Domestic companies have accumulated rich experience in chemical modifications and liver-targeted delivery technologies, covering high-value areas such as hyperlipidemia, hypertension, hepatitis B, and weight loss [8] Summary by Sections Industry Overview - The report focuses on the pharmaceutical and biotechnology industry in China, specifically on small nucleic acid drugs and their evolving delivery technologies [5][6] Investment Recommendations and Targets - The report lists several investment targets, including: - YK Pharma (688658, Buy) - Hengrui Medicine (600276, Buy) - Xinda Biopharma (01801, Not Rated) - Other companies such as Chengdu XianDao (688222, Not Rated), Reborn Biotech (06938, Not Rated), and others [3]

Group 1 - The report indicates that the recent market adjustment pressure has been released, leading to a rebound, with popular sectors experiencing valuation recovery after a rapid decline [6] - The report maintains a cautiously optimistic view for February, suggesting that while the A-share index may struggle, there is potential for valuation recovery in the H-share market [6] - The report emphasizes the importance of mid-cap blue-chip stocks with medium risk characteristics, particularly in the agricultural sector, which is expected to continue its strength [6] Group 2 - The report highlights that during the "14th Five-Year Plan" period, China's wind and solar installations are expected to maintain high growth rates, with specific segments like offshore wind power and perovskite solar cells showing significant growth potential [6] - It forecasts that energy storage installations will achieve over 50% growth by 2025, driven by the high demand for renewable energy [6] - The report identifies high-growth technology-related stocks in the renewable energy sector as key investment opportunities [6] Group 3 - The report discusses the upcoming mass production of humanoid robots by Tesla, indicating increased certainty in this area, particularly regarding dexterous hands and the humanization of robots [4] - It suggests that the demand for components such as sensors and flexible protective layers will rise as robots become more human-like [4] - The report points out that companies with proven manufacturing and management capabilities in automotive and engineering machinery parts are likely to gain higher market shares [4]

Investment Rating - The report maintains a "Positive" investment rating for the media industry in China, indicating an expectation of returns exceeding the market benchmark by over 5% [3][12]. Core Insights - The application of AI in the gaming industry is transitioning from B2B to B2C, with many high DAU games leveraging natural language AI game engines to drive user co-creation, resulting in significant growth in both game content and DAU [6]. - The report highlights key companies with advantages in gaming channels and high DAU, recommending Tencent Holdings (00700, Buy), NetEase-S (09999, Buy), and others for investment [6]. - The report emphasizes the importance of companies with significant project reserves for the year, suggesting a focus on 37 Interactive Entertainment (002555, Accumulate) and Perfect World (002624, Accumulate) [6]. Summary by Sections Industry Overview - The report discusses the impact of AI game editors, noting that Tencent's "Peacekeeper Elite" has surpassed 33 million DAU, indicating a shift from B2B to C-end empowerment in the gaming AI engine sector [7]. Investment Recommendations - Companies recommended for investment include Tencent Holdings, NetEase-S, and others with strong positions in gaming channels and DAU [6]. - Companies with key project reserves for the year, such as 37 Interactive Entertainment and Perfect World, are also highlighted for potential investment [6]. Market Dynamics - The report notes that the domestic AI game editor technology is ready for commercial application, with companies like Tencent and NetEase leading the way in integrating AI tools into high DAU games [7]. - The report assesses the limitations of overseas models like Genie3, indicating that they currently lack the necessary support for B-end game production and have uncertain playability for C-end users [7].